US$ 28.53
global glp-1 obesity drug market size forecast 2030 to Hit USD 66.57 Billion by 2035 GLP-1 obesity drugs to reshape
Description
Contrariwise, in the study by Jensterle et al

Its a functional disorder affecting your stomach nerves and muscles

They share a common therapeutic value: improved glycaemic control, weight reduction, and protection against cardiovascular and renal outcomes
The majority of nausea, vomiting, and/or diarrhea events occurred during a dose increase and decreased over time

I havent seen convincing evidence that any of these will make a significant impact on weight loss, Dr